BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 962 filers reported holding BAXTER INTL INC in Q3 2014. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $420,000 | -76.1% | 12,787 | -49.0% | 0.30% | -74.4% |
| Q2 2015 | $1,754,000 | +117.6% | 25,081 | +113.2% | 1.15% | +116.4% |
| Q1 2015 | $806,000 | +0.9% | 11,763 | +7.9% | 0.53% | 0.0% |
| Q4 2014 | $799,000 | +5.0% | 10,898 | +2.8% | 0.53% | +0.2% |
| Q3 2014 | $761,000 | +2.1% | 10,600 | +2.8% | 0.53% | +0.6% |
| Q2 2014 | $745,000 | +6.0% | 10,316 | +8.0% | 0.53% | -1.5% |
| Q1 2014 | $703,000 | +11.2% | 9,548 | +5.0% | 0.54% | +11.7% |
| Q4 2013 | $632,000 | – | 9,092 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |